Crysvita Effective at Easing Children’s Pain and Aiding Life Quality, Trial Shows
Switching from conventional therapy to Crysvita (burosumab) leads to clinically relevant reductions in pain and fatigue, and better quality of life, in children with X-linked hypophosphatemia (XLH) ages 5 to 12, according to data from a Phase 3 clinical trial. These findings in patient-reported outcomes add to previous results…